{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:25:42Z","timestamp":1790414742063,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[1997,8,1]],"date-time":"1997-08-01T00:00:00Z","timestamp":870393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1997,8,1]],"date-time":"1997-08-01T00:00:00Z","timestamp":870393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1997,8]]},"DOI":"10.1136\/ard.56.8.481","type":"journal-article","created":{"date-parts":[[2008,12,6]],"date-time":"2008-12-06T00:32:33Z","timestamp":1228523553000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide"],"prefix":"10.1016","volume":"56","author":[{"given":"Ignacio","family":"Martin-Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther A","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R V","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.56.8.481_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis).","volume":"ii","author":"Walton","year":"1958","journal-title":"BMJ"},{"key":"10.1136\/ard.56.8.481_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis. Prospective clinical and therapeutic experience with 85 patients for 21 years.","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.56.8.481_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener\u2019s granulomatosis: Studies in eighteen patients and a review of the literature.","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"key":"10.1136\/ard.56.8.481_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis.","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.56.8.481_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis.","volume":"301","author":"Fauci","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.56.8.481_bib6","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(89)92416-1","article-title":"Cyclophosphamide in severe polymyositis.","volume":"i","author":"Bombardieri","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.56.8.481_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.7326\/0003-4819-106-1-79","article-title":"NIH Conference: Lupus nephritis.","volume":"106","author":"Balow","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.56.8.481_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs.","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.56.8.481_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM198408233110802","article-title":"Effect of treatment on the evolution of renal abnormalities in lupus nephritis.","volume":"311","author":"Balow","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.56.8.481_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780340803","article-title":"Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only.","volume":"34","author":"Steinberg","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.56.8.481_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0002-9343(84)90654-5","article-title":"Intravenous cyclophosphamide plus methylprednisolone in the treatment of systemic rheumatoid vasculitis.","volume":"76","author":"Scott","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.56.8.481_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/ard.51.7.885","article-title":"The short-term effect of pulse cyclophosphamide in the treatment of connective tissue diseases.","volume":"51","author":"Haga","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.56.8.481_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/096120339100100106","article-title":"Weekly low dose pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study.","volume":"1","author":"Houssiau","year":"1991","journal-title":"Lupus"},{"key":"10.1136\/ard.56.8.481_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus.","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.56.8.481_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis.","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.56.8.481_bib16","first-page":"247","article-title":"Enzyme immunoassays for the detection of IgG and IgM anti-ds DNA antibodies. Clinical significance and specificity.","volume":"5","author":"Tzioufas","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.56.8.481_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(80)92703-8","article-title":"Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulfonate sodium (Mesnum) in patients with advanced carcinoma.","volume":"ii","author":"Bryant","year":"1980","journal-title":"Lancet"},{"key":"10.1136\/ard.56.8.481_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0140-6736(92)91505-3","article-title":"Response of cyclophosphamide resistant Wegener\u2019s granulomatosis to etoposide.","volume":"340","author":"D\u2019Cruz","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/ard.56.8.481_bib19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide.","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol"},{"key":"10.1136\/ard.56.8.481_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0049-0172(86)90020-X","article-title":"Cytotoxic drugs: their clinical application to the rheumatic diseases.","volume":"15","author":"Clements","year":"1986","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.56.8.481_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.1780310402","article-title":"Cyclophosphamide induced bladder toxicity in Wegener\u2019s granulomatosis.","volume":"31","author":"Stillwell","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.56.8.481_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener\u2019s granulomatosis: analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.56.8.481_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","article-title":"Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.56.8.481_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.1992.01680110090012","article-title":"Drug eruptions from mesna after cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis.","volume":"128","author":"Zonzits","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.56.8.481_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/ard.56.8.481_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/096120339500400205","article-title":"New York University\/ Hospital for joint diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis.","volume":"4","author":"Belmont","year":"1995","journal-title":"Lupus"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724402173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724402173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.56.8.481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:52:21Z","timestamp":1740970341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724402173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["S0003496724402173"],"URL":"https:\/\/doi.org\/10.1136\/ard.56.8.481","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1997,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.56.8.481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1997 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}